Genentech Backtracks In Synagis Dispute

Law360 (November 2, 2006, 12:00 AM EST) -- Genentech Inc. has pulled a complaint against biotech competitor MedImmune Inc. which alleged that MedImmune’s Synagis, used to stave off dangerous respiratory tract infections in infants, violated its patents.

As it wrangles with Genentech over a patent-license dispute over the same product before the U.S. Supreme Court, MedImmune said it had never received this complaint, according to a filing with the U.S. Securities and Exchange Commission on Wednesday. Genentech filed the complaint in January in the U.S. District Court for the Eastern District of Texas....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.